Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences Q3 Net Loss Widens to $8.0 Million from $4.4 Million

Negative Impact 3 of 5 earnings

Cellectar Biosciences reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share, up from $4.4 million, or $1.41 per share, a year earlier. Research and development expenses rose to $5.4 million from $2.5 million, tied to the start of its Phase 3 confirmatory trial and its CLR 125 Phase 1b trial. The company said its September 30, 2026 cash balance is adequate to fund budgeted operations into the second quarter of 2027.

Key points

  • Q3 2026 net loss was $8.0 million, or $0.46 per share, versus $4.4 million, or $1.41 per share, in Q3 2025.
  • R&D expenses were about $5.4 million versus about $2.5 million a year earlier; G&A expenses were about $2.7 million versus $2.3 million.
  • Cash and cash equivalents were $24.6 million at September 30, 2026, including net proceeds of about $31.7 million from a May 2026 offering.
  • The company plans to dose the first patient in its Phase 3 confirmatory trial in Q1 2027 and submit an NDA seeking accelerated approval in 1H 2027.

The filing

CompanyCellectar Biosciences, Inc. (CLRB)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:25 AM ET
Accession number0001104659-26-124790

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:32 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.